Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2012

The Pharma Closeout tracks 38 deals, $73.1B in disclosed deal value, 34 with a post-close Outcome Score for the year 2012.

Median Critic Score: 75  ·  Median Outcome Score: 41

Best outcome: Watson Pharmaceuticals, Inc. / Actavis Group (97)  ·  Weakest outcome: Bristol-Myers Squibb Company / Inhibitex Inc. (8)

All 38 deals

• Watson Pharmaceuticals, Inc. / Actavis Group — 2012 · $5.9B · Worked — the deal delivered on its rationale.
• Amgen Inc. / Micromet Inc. — 2012 · $1.2B · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Theravance, Inc. — 2012 · $213M · Worked — the deal delivered on its rationale.
• Hologic Inc. / Gen-Probe Incorporated — 2012 · $3.8B · Worked — the deal delivered on its rationale.
• Johnson & Johnson (Janssen Biotech Inc.) / Genmab A/S — 2012 · $3.0B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Bristol-Myers Squibb Company / Amylin diabetes alliance — 2012 · $3.5B · Worked — the deal delivered on its rationale.
• GSK plc / Human Genome Sciences — 2012 · $3.6B · Largely worked — most objectives met.
• Reckitt Benckiser Group plc / Schiff Nutrition International, Inc. — 2012 · $1.4B · Largely worked — most objectives met.
• Jazz Pharmaceuticals plc / EUSA Pharma — 2012 · $700M · Largely worked — most objectives met.
• Allergan, Inc. / SkinMedica, Inc. — 2012 · $375M · Mixed — partial payoff, real shortfalls.
• Aetna Inc. / Coventry Health Care, Inc. — 2012 · $7.3B · Mixed — partial payoff, real shortfalls.
• Nestle SA / Pfizer Nutrition (Pfizer Inc. infant nutrition unit) — 2012 · $11.8B · Mixed — partial payoff, real shortfalls.
• Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc. — 2012 · $230M · Mixed — partial payoff, real shortfalls.
• GenturaDx / LUMINEX CORP — 2012 · $50M · Mixed — partial payoff, real shortfalls.
• HeartWare / WorldHeart — 2012 · $8M · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Ltd. / URL Pharma, Inc. — 2012 · $800M · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / AC Immune SA — 2012 · $718M · Underwhelmed — fell short of the thesis.
• Roche Holding AG / AC Immune SA — 2012 · $570M · Underwhelmed — fell short of the thesis.
• Bristol-Myers Squibb Company / Amylin Pharmaceuticals — 2012 · $5.3B · Underwhelmed — fell short of the thesis.
• Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. — 2012 · $90M · Underwhelmed — fell short of the thesis.
• Novartis AG / Fougera Pharmaceuticals Inc. — 2012 · $1.5B · Underwhelmed — fell short of the thesis.
• Sun Pharmaceutical Industries Ltd. / URL Pharma, Inc. (generics business) — 2012 · $60M · Underwhelmed — fell short of the thesis.
• Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation — 2012 · $2.6B · Underwhelmed — fell short of the thesis.
• Dainippon Sumitomo Pharma Co., Ltd. / Boston Biomedical, Inc. — 2012 · $2.6B · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Ardea Biosciences, Inc. — 2012 · $1.3B · Did not work — the deal failed to deliver.
• Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (API and R&D facilities) — 2012 · $200M · Did not work — the deal failed to deliver.
• Pfizer Inc. / NextWave Pharmaceuticals, Inc. — 2012 · $700M · Did not work — the deal failed to deliver.
• Pernix Therapeutics Holdings, Inc. / Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals, Inc. — 2012 · $102M · Did not work — the deal failed to deliver.
• Celgene Corporation / Avila Therapeutics, Inc. — 2012 · $925M · Did not work — the deal failed to deliver.
• Shire plc / Pervasis Therapeutics, Inc. — 2012 · $200M · Did not work — the deal failed to deliver.
• Gilead Sciences, Inc. / YM BioSciences Inc. — 2012 · $510M · Did not work — the deal failed to deliver.
• AbbVie Inc. / Stemcentrx Inc. — 2012 · $5.8B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Inhibitex Inc. — 2012 · $2.5B · Did not work — the deal failed to deliver.
• Shire plc / FerroKin BioSciences, Inc. — 2012 · $325M · Did not work — the deal failed to deliver.
• Bayer AG / Schiff Nutrition International, Inc. — 2012 · $1.2B
• Merck KGaA / Threshold Pharmaceuticals, Inc. — 2012 · $550M
• Roche Holding AG / AC Immune SA — 2012 · $418M
• Merck & Co. Inc. / Endocyte, Inc. — 2012 · $1.0B

← Deal Library  ·  Interactive search  ·  How we score deals